Molecular dynamics studies of the STAT3 homodimer:DNA complex: relationships between STAT3 mutations and protein-DNA

Jarmila Husby1, Alan K Todd, Shozeb M Haider

  • 1CRUK Biomolecular Structure Group, UCL School of Pharmacy, University College London, WC1N 1AX London, UK.

Insights

Understanding Signal Transducers and Activators of Transcription 3 (STAT3) dynamics is key for developing new cancer drugs. Molecular dynamics simulations reveal how STAT3 interacts with DNA, aiding the design of small-molecule inhibitors.

Area of Science:

  • Biochemistry and Molecular Biology
  • Structural Biology
  • Cancer Research

Background:

  • Signal Transducers and Activators of Transcription (STAT) proteins regulate cytokine signaling.
  • STAT3 is frequently overexpressed in various human cancers, making it a significant drug target.
  • Understanding STAT3's monomer and dimer dynamics is crucial for designing inhibitors.

Purpose of the Study:

  • To investigate the dynamics of the STAT3 dimer interface and latent monomer using molecular dynamics simulations.
  • To elucidate STAT3's protein-DNA interactions and conformational changes.
  • To identify key residues and structural features for small-molecule inhibitor design.

Main Methods:

  • Utilized 50 ns molecular dynamics (MD) simulations.
  • Simulated the activated STAT3 homodimer:DNA complex and the latent unphosphorylated STAT3 monomer in an explicit water environment.
  • Analyzed protein-DNA interactions, conformational changes, and dimer interface dynamics.

Main Results:

  • Detailed the mechanism of STAT3 transcription factor interaction with DNA.
  • Identified key residues at the protein-DNA interface, including the role of water molecules.
  • Mapped mutations within the DNA-binding domain to specific protein-DNA contacts and analyzed their structural stability.

Conclusions:

  • The study provides insights into STAT3-DNA recognition and conformational dynamics.
  • Identified critical structural elements of the STAT3 dimer interface relevant for drug discovery.
  • The findings serve as a foundation for developing novel small-molecule STAT3 inhibitors for cancer therapy.